亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Complement Inhibition

技術優勢
Control over this interaction inhibits the complement cascade andprevents cell membrane damage, cell death, and organ rejection.
技術應用
Pharmaceutical industry and biotech companies interested in early stagedevelopments with a potential in a wide range of application.
詳細技術說明
Compounds modulating CD59 mediated complement activity,compositions including these compounds, and methods of makingand using the compounds are available for licensing. Thesecompounds responsible for complement inhibition react at thebinding site for CD59-C9 interactions. Compounds can be derivedusing this basic amino acid sequence described andcorresponding three dimensional structure of the protein using anyof several techniques known to those skilled in the art, includingrational drug design.Those compounds imitating the structure and/or function of the peptide region bind to the active portions of human C9, as well as modified peptides. The compounds can be administered locally or systemically in any amount effective to either inhibit complement or block the inhibition of complement, in a patient in need of treatment. This discovery describes the interactions of C5b-9 complex with CD59 that shut down the complement system including the mechanism andregion of binding.Filed in US, PCT, EPC, and other foreign countries. Technology co-owned with the Oklahoma Medical Research Foundation.
*Abstract
Compounds modulating CD59 mediated complement activity,compositions including these compounds, and methods of makingand using the compounds are available for licensing.
*Principal Investigation

Name: Peter J. Sims

Department:

國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備